Views & Analysis What HCPs say about Roche's breast cancer drug The online conversations about breast cancer drug Kadcyla before it was approved by NICE.
News Biosimilars manufacturers close in on Roche cancer blockbust... FDA panel backs Herceptin and Avastin biosimilars.
News Angle poised to take on US cancer diagnostics market Circulating tumour cell test could help select drug therapy.
News Kisqali set for approval - but likely to hit same NICE obsta... Concerns that NICE will reject Kisqali like it did Ibrance.
News Kadcyla finally gets OK after price cut and NICE concessions Roche’s breast cancer drug Kadcyla is set for regular NHS funding in England after the company finally agreed a deal with NICE.
News Puma gains as Roche breast cancer combo disappoints ASCO serves up shock as Roche's data disappoints
News US pharma tariffs of up to 100% finalised by Trump Trump signs his pharma tariffs executive order, which won't affect most large pharma groups but could deal a hefty blow to smaller companies.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
